O’Melveny Advises on First IPO of an AI Nano-Delivery Company in US$270 Million Hong Kong Chapter 18C Listing of Metis TechBio
May 13, 2026
FOR IMMEDIATE RELEASE
HONG KONG—May 13, 2026—O’Melveny represented joint sponsors and other underwriters in the initial public offering and listing of Metis TechBio Co., Ltd. (“Metis TechBio”, 7666.HK) on the Main Board of The Stock Exchange of Hong Kong. Listed under Chapter 18C (Specialist Technology Companies) of the Hong Kong Listing Rules, Metis TechBio raised approximately HK$2.1 billion (approximately US$270 million), assuming the over-allotment option is not exercised.
O’Melveny acted as Hong Kong and U.S. counsel to the joint sponsors including Jefferies Hong Kong Limited, Deutsche Securities Asia Limited, and CITIC Securities (Hong Kong) Limited, overall coordinators including Jefferies Hong Kong Limited, Deutsche Bank AG, Hong Kong Branch, CLSA Limited and CMB International Capital Limited, and other underwriters. The cornerstone investors included 18 leading institutions subscribing approximately US$148 million, a record cornerstone investment amount in the AI pharma listing space.
Founded in 2020, Metis TechBio is the world’s first biotech company focused on AI-powered nanomaterial delivery. The transaction is widely recognized as the “world’s first AI nano-delivery IPO”. The company’s proprietary NanoForge platform, powered by the industry’s first, largest, and most diverse lipid library (comprising over 10 million lipids), can design targeted delivery systems that deliver to eight major organs or tissues with precision, including the liver, lungs, spleen, and muscles. The platform reduces preclinical formulation timelines from approximately one to two years to less than three months.
This transaction further solidifies O’Melveny’s leading position in healthcare IPOs, demonstrating our continued depth of expertise at the cutting-edge intersection of healthcare and AI. Previously, O’Melveny advised on the IPO of leading medical imaging AI company Diagens Biotechnology. O’Melveny has advised on the successful listings of more than 50 pharmaceutical, healthcare and life sciences companies, including 22 IPOs listed via Chapter 18A.
The O’Melveny team was led by partners Ke Geng, Ke Zhu and Vincent Wang. The core team members included counsel Berton Wang, China associate Jie Lian, legal managers Ruby Chong and Belinda Zhu, legal consultant Hanyun Lyu, and trainee solicitors Wilson Tang and Cheryl Chan. Associate Jingwei Huang also made valuable contributions.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #